Patient Preferences for a Polypill for the Prevention of Cardiovascular Diseases

Annals of Pharmacotherapy

Volumn 49, Issue 5, 2015, Pages 528-539

  Laba, Tracey Lea ^a   Howard, Kirsten ^b   Rose, John ^c   Peiris, David ^a   Redfern, Julie ^a   Usherwood, Tim ^d   Cass, Alan ^e   Patel, Anushka ^a   Jan, Stephen ^a  

^a GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

adherence; cardiovascular disease; cost; discrete choice experiment; patient preference; polypill

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD PRESSURE LOWERING AGENT; CARDIOVASCULAR AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; DRUG COMBINATION;

AGED; ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT PREFERENCE; PILL; POLYPILL; PRIORITY JOURNAL; TABLET; CARDIOVASCULAR DISEASES; DRUG COMBINATION; ECONOMICS; HEALTH CARE COST; INFORMATION PROCESSING; MIDDLE AGED; PRACTICE GUIDELINE; STATISTICAL MODEL;

AGED; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DATA COLLECTION; DRUG COMBINATIONS; FEMALE; GUIDELINE ADHERENCE; HEALTH EXPENDITURES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MODELS, ECONOMETRIC; PATIENT PREFERENCE;

EID: 84928230401     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028015570468     Document Type: Article

References (38)

1. World Health Organization. Global Atlas on Cardiovascular Disease Prevention and Control. Policies, Strategies and Interventions. http://www.who.int/cardiovascular_diseases/publications/atlas_cvd/en/. Accessed December 8, 2014.
2. Mathers CD,Loncar D.Projections of global mortality and burden of disease from 2002 to 2030.PLoS Med. 2006;3:e442
3. Yusuf S,Islam S,Chow CK, et al.Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.Lancet. 2011;378:1231-1243
4. Simons LA,Ortiz M,Calcino G.Persistence with antihypertensive medication: Australia-wide experience, 2004-2006.Med J Aust. 2008;188:224-227
5. Bowry A,Shrank W,Lee J,Stedman M,Choudhry N.A systematic review of adherence to cardiovascular medications in resource-limited settings.J Gen Intern Med. 2011;26:1479-1491
6. Ho PM,Bryson CL,Rumsfeld JS.Medication adherence: its importance in cardiovascular outcomes.Circulation. 2009;119:3028-3035
7. SabateE. Adherence to Long Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organisation; 2003. http://www.who.int/chp/knowledge/publications/adherence_report/en/. Accessed December 8, 2014.
8. Sherrill B,Halpern M,Khan S,Zhang J,Panjabi S.Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence.J Clin Hypertens (Greenwich). 2011;13:898-909
9. Wald NJ,Law MR.A strategy to reduce cardiovascular disease by more than 80%.Br Med J (Clin Res Ed). 2003 1419;326:
10. LonnEBoschJTeoKKPaisPXavierDYusufS. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation. 2010;122:2078-2088. doi:http://dx.doi.org/10.1161/CIRCULATIONAHA.109.873232.
11. LafeberMSpieringWSinghK. The cardiovascular polypill in high-risk patients. Eur J Prev Cardiol. 2012;19:1234-1242. doi:http://dx.doi.org/10.1177/1741826711428066.
12. Thom S,Poulter N,Field J, et al.Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.JAMA. 2013;310:918-929
13. Liu H,Patel A,Brown A, et al.Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non indigenous people at high cardiovascular risk.BMC Public Health. 2010;10:
14. Patel A,Cass A,Peiris D, et al.A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk [published online March 27, 2014].Eur J Prev Cardiol.:
15. Jan S,Usherwood T,Brien JA, et al.What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study.BMJ Open. 2011;1:e000372
16. Lancsar E,Louviere J.Conducting discrete choice experiments to inform healthcare decision making: a user’s guide.Pharmacoeconomics. 2008;26:661-677
17. Lamiraud K,Geoffard P-Y.Therapeutic non-adherence: a rational behavior revealing patient preferences?.Health Econ. 2007;16:1185-1204
18. HorneRWeinmanJBarberNElliottRMorganM. Concordance, adherence and compliance in medicine taking: report for the National Co-ordinating Centre for NHS Delivery and Organisation R & D (NCCSDO). http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0009/64494/FR-08-1412-076.pdf. Accessed December 8, 2014.
19. Bridges JF,Hauber AB,Marshall D, et al.Conjoint analysis applications in health—a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force.Value Health. 2011;14:403-413
20. LabaT-L. Medication Adherence in Chronic Disease [thesis]. Sydney, Australia: Faculty of Pharmacy, University of Sydney; 2013. http://ses.library.usyd.edu.au/handle/2123/9546. Accessed December 8, 2014.
21. RoseJBliemerMCJ. Constructing Efficient Choice Experiments: Report ITLS-WP-05-07. Sydney, Australia: Institute of Transport and Logistics Studies, University of Sydney; 2005. http://ws.econ.usyd.edu.au/itls/wp-archive/itls_wp_05-07.pdf. Accessed December 8, 2014.
22. Ngene [computer program]. Version 1.0. ChoiceMetrics;2009. http://www.choice-metrics.com/. Accessed January 17, 2014.
23. Hensher DA,Rose JM,Greene WHApplied Choice Analysis: A Primer. Cambridge, UK: Cambridge University Press; 2005:
24. Hauber BA,Mohamed AF,Beam C,Medjedovic J,Mauskopf J.Patient preferences and assessment of likely adherence to hepatitis C virus treatment.J Viral Hepat. 2011;18:619-627
25. Bliemer MCJ,Rose JM.Confidence intervals of willingness-to-pay for random coefficient logit models.Transportation Res Part B Methodological. 2013;58:199-214
26. Webster RJ,Heeley EL,Peiris DP,Bayram C,Cass A,Patel AA.Gaps in cardiovascular disease risk management in Australian general practice.Med J Aust. 2009;191:324-329
27. Austvoll-Dahlgren A,Aaserud M,Vist G, et al.Pharmaceutical policies: effects of cap and co-payment on rational drug use.Cochrane Database Syst Rev. 2008; (1): CD007017
28. Australian Government Department of Health. Pharmaceutical Benefits Scheme (PBS). http://pbs.gov.au/info/about-the-pbs. Accessed June 30, 2014.
29. Laba T-L,Usherwood T,Leeder S, et al.Copayments for healthcare: what is their real cost?.Aust Health Rev.:
30. EssueBUsherwoodTLabaT-L. Out-of-pocket costs of health care in Australia. Submission to the Senate Standing Committee on Community Affairs. http://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_Affairs/Australian_healthcare/Submissions. Accessed December 8, 2014.
31. DoggettH. Empty pockets: why co-payments are not the solution. https://www.chf.org.au/pdfs/chf/Empty-Pockets_Why-copayments-are-not-the-solution_Final-OOP-report.pdf. Accessed December 8, 2014.
32. Kemp A,Roughead E,Preen D,Glover J,Semmens J.Determinants of self-reported medicine underuse due to cost: a comparison of seven countries.J Health Serv Res Policy. 2010;15:106-114
33. Kemp A,Glover J,Preen DB,Bulsara M,Semmens J,Roughead EE.From the city to the bush: increases in patient co-payments for medicines have impacted on medicine use across Australia.Aust Health Rev. 2013;37:4-10
34. Jan S,Essue BM,Leeder SR.Falling through the cracks: the hidden economic burden of chronic illness and disability on Australian households.Med J Aust. 2012;196:29-31
35. Hynd A,Roughead EE,Preen DB,Glover J,Bulsara M,Semmens J.The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.Pharmacoepidemiol Drug Saf. 2008;17:1091-1099
36. Holt S.New Zealand general practitioners’ opinions of the polypill concept.N Z Med J. 2009;122:116-117
37. Burns K,Turnbull F,Patel A,Peiris D.Opinions of community pharmacists on the value of a cardiovascular polypill as a means of improving medication compliance.Int J Pharm Pract. 2012;20:155-163
38. Bryant L,Martini N,Chan J, et al.Could the polypill improve adherence? The patient perspective.J Prim Health Care. 2013;5:28-35